Copyright
©The Author(s) 2020.
World J Orthop. Dec 18, 2020; 11(12): 559-572
Published online Dec 18, 2020. doi: 10.5312/wjo.v11.i12.559
Published online Dec 18, 2020. doi: 10.5312/wjo.v11.i12.559
Table 1 Single stage revision outcomes for total knee arthroplasty and total hip arthroplasty
| Ref. | Year | PJI | Cases | Reinfection | Follow-up (in year) |
| Freeman et al[47] | 1985 | Knee | 8 | 0 | 2 |
| Göksan et al[48] | 1992 | Knee | 18 | 2 (11%) | 5 |
| Scott et al[49] | 1993 | Knee | 10 | 3 (30%) | |
| Silva et al[50] | 2002 | Knee | 37 | 4 (11%) | 5 |
| Buechel et al[51] | 2004 | Knee | 22 | 2 (9%) | 10 |
| Whiteside et al[52] | 2011 | Knee | 18 | 1 (6%) | 5.2 |
| Parkinson et al[53] | 2011 | Knee | 22 | 0 | 2 |
| Singer et al[54] | 2012 | Knee | 63 | 3 (5%) | 3 |
| Klatte et al[55] | 2014 | Knee | 4 | 1 (25%) | 2.1 |
| Tibrewal et al[13] | 2014 | Knee | 50 | 1 (2%) | 10.5 |
| Haddad et al[14] | 2015 | Knee | 28 | 0 | 6.5 |
| Labruyère et al[56] | 2015 | Knee | 9 | 0 | 5 |
| Holland et al[57] | 2019 | Knee | 26 | 1 (4%) | 5.3 |
| Siddiqi et al[58] | 2019 | TKA | 57 | 8 (14%) | 4.4 |
| Abdelaziz et al[59] | 2020 | TKA | 72 | 8 (11%) | 4.2 |
| Ji et al[60] | 2020 | Both | 51 | 5 (10%) | 4.4 |
| Carlsson et al[61] | 1978 | Hip | 77 | 17 (22%) | |
| Hughes et al[62] | 1979 | Hip | 13 | 4 (31%) | |
| Buchholz et al[2] | 1981 | Hip | 640 | 130 (20%) | 4.3 |
| Miley et al[63] | 1982 | Hip | 47 | 6 (13%) | 4 |
| Weber et al[64] | 1986 | Hip | 8 | 2 (25%) | 6 |
| Wroblewski et al[4] | 1986 | Hip | 102 | 9 (9%) | 3.2 |
| Sanzén et al[65] | 1988 | Hip | 102 | 25 (25%) | 7 |
| Hope et al[66] | 1989 | Hip | 72 | 9 (13%) | 3.75 |
| Raut et al[67] | 1994 | Hip | 57 | 8 (14%) | 7.3 |
| Mulcahy et al[68] | 1996 | Hip | 15 | 0 | 4 |
| Ure et al[69] | 1998 | Hip | 22 | 0 | 10.5 |
| Callaghan et al[6] | 1999 | Hip | 24 | 2 (8%) | 10 |
| Rudelli et al[70] | 2008 | Hip | 32 | 2 (6%) | 5 |
| Winkler et al[71] | 2008 | Hip | 37 | 3 (8%) | 4.4 |
| Yoo et al[72] | 2008 | Hip | 12 | 1 (8%) | 7.2 |
| Oussedik et al[39] | 2010 | Hip | 11 | 0 | 6.8 |
| De Man et al[40] | 2011 | Hip | 22 | 0 | 3.8 |
| Klouche et al[11] | 2012 | Hip | 38 | 0 | 2 |
| Choi et al[73] | 2013 | Hip | 17 | 3 (18%) | 5.1 |
| Hansen et al[26] | 2013 | Hip | 27 | 8 (30%) | 2.25 |
| Bori et al[46] | 2014 | Hip | 24 | 1 (4%) | 3.6 |
| Jenny et al[74] | 2014 | Hip | 65 | 17 (26%) | 5 |
| Klatte et al[55] | 2014 | Hip | 6 | 0 | 2.1 |
| Wolf et al[27] | 2014 | Hip | 37 | 24 (65%) | 2 |
| Zeller et al[5] | 2014 | Hip | 157 | 8 (5%) | 3.4 |
| Ebied et al[75] | 2016 | Hip | 33 | 1 (3%) | 6 |
| Ilchman et al[76] | 2016 | Hip | 39 | 0 | 6.6 |
| Born et al[77] | 2016 | Hip | 28 | 0 | 7 |
| Lange et al[78] | 2017 | Hip | 56 | 5 (91%) | 4 |
| Whiteside et al[79] | 2017 | Hip | 21 | 1 (95%) | 5.2 |
| Zahar et al[80] | 2018 | Hip | 85 | 5 (6%) | 10.5 |
| Bori et al[81] | 2018 | Hip | 19 | 1 (5%) | |
| Wolff et al[82] | 2019 | Hip | 26 | 1 (96%) | 15 |
| Ji et al[24] | 2019 | Hip | 111 | 12 (11%) | 4.8 |
Table 2 Bactericidal antibiotics vs bacteriostatic antibiotics
| Bactericidal antibiotics | Bacteriostatic |
| Aminoglycosides, cephalosporins, fluoroquinolones, metronidazole, penicillin, vancomycin | Chloramphenicol, clindamycin, erythromycin, sulfamethoxazole, tetracycline, trimethoprim |
Table 3 International Consensus Meeting 2018 Guidelines for prosthetic joint infection for hip and knee arthroplasty
| Major criteria | |||
| Two positive cultures of the same organism / Sinus tract with communication to the joint or prosthesis | |||
| Minor criteria | |||
| Criteria | Acute threshold | Chronic threshold | Score |
| CRP (mg/L) or D Dimer (ug/L) | 100; unknown | 10; 860 | 2 |
| ESR (mm/h) | No role | 30 | 1 |
| Synovial WBC or leukocyte esterase or alpha defensin | 10000; ++; 1.0 | 3000; ++; 1.0 | 2 |
| Synovial PMN % | 90 | 70 | 2 |
| Single positive culture | 2 | ||
| Positive histology | 3 | ||
| Positive intraoperative purulence | 3 | ||
Table 4 McPherson host class comorbidities
| Systemic host compromising factors | ||
| Age ≥ 80 yr | Alcoholism | Chronic cellulitis or dermatitis |
| Chronic indwelling catheter | Malnutrition (albumin < 3 g/dL) | Current nicotine use |
| Diabetes | Hepatic insuffiency | Immunosuppressive drugs |
| Malignancy (history or active) | Pulmonary insuffiency | Renal failure on dialysis |
| Systemic inflammatory disease | Systemic immune compromised disease or infection (HIV, AIDS) | |
Table 5 International consensus meeting indications and contra-indications for single stage revision for prosthetic joint infection
| Indications | Contra-indications |
| Non-immunocompromised host | Severe damage to soft tissues were direct closure not possible or inexcisable complex sinus tract with old scar |
| Absence of systemic sepsis | Culture negative PJI |
| Minimal bone/soft tissue loss allowing primary closure | Inability to perform radical debridement |
| Isolation of pathologic organism preoperatively | Unable to give local antibiotic treatment |
| Known sensitivities to bactericidal treatment | No proper bone stock available for fixation |
- Citation: Lum ZC, Holland CT, Meehan JP. Systematic review of single stage revision for prosthetic joint infection. World J Orthop 2020; 11(12): 559-572
- URL: https://www.wjgnet.com/2218-5836/full/v11/i12/559.htm
- DOI: https://dx.doi.org/10.5312/wjo.v11.i12.559
